Your browser doesn't support javascript.
loading
Implications for driving based on the risk of seizures after ischaemic stroke.
Schubert, Kai Michael; Bicciato, Giulio; Sinka, Lucia; Abraira, Laura; Santamarina, Estevo; Álvarez-Sabín, José; Ferreira-Atuesta, Carolina; Katan, Mira; Scherrer, Natalie; Terziev, Robert; Döhler, Nico; Erdélyi-Canavese, Barbara; Felbecker, Ansgar; Siebel, Philip; Winklehner, Michael; von Oertzen, Tim J; Wagner, Judith N; Gigli, Gian Luigi; Nilo, Annacarmen; Janes, Francesco; Merlino, Giovanni; Valente, Mariarosaria; Zafra-Sierra, María Paula; Mayor-Romero, Luis Carlos; Conrad, Julian; Evers, S; Lochner, Piergiorgio; Roell, Frauke; Brigo, Francesco; Bentes, Carla; Peralta, Rita; Pinho E Melo, Teresa; Keezer, Mark R; Duncan, John Sidney; Sander, Josemir W; Tettenborn, Barbara; Koepp, Matthias; Galovic, Marian.
  • Schubert KM; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Bicciato G; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Sinka L; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Abraira L; Department of Neurology, Schulthess Klinik, Zurich, Switzerland.
  • Santamarina E; Epilepsy Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Álvarez-Sabín J; Epilepsy Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Ferreira-Atuesta C; Epilepsy Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Katan M; Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG & Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK.
  • Scherrer N; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Terziev R; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Döhler N; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Erdélyi-Canavese B; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Felbecker A; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Siebel P; Department of Neurology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.
  • Winklehner M; Specialist Clinic for Neurorehabilitation, Beelitz Hospitals, Beelitz, Germany.
  • von Oertzen TJ; Department of Neurology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.
  • Wagner JN; Department of Neurology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.
  • Gigli GL; Department of Neurology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.
  • Nilo A; Department of Neurology, Kepler University Hospital, Johannes Kepler Universitat Linz, Linz, Austria.
  • Janes F; Department of Neurology, Kepler University Hospital, Johannes Kepler Universitat Linz, Linz, Austria.
  • Merlino G; Department of Neurology, Kepler University Hospital, Johannes Kepler Universitat Linz, Linz, Austria.
  • Valente M; Department of Neurology, Evangelisches Klinikum Gelsenkirchen, Academic Hospital University Essen-Duisburg, Gelsenkirchen, Germany.
  • Zafra-Sierra MP; Department of Medicine, University of Udine and Clinical Neurology, University of Udine, Udine, Italy.
  • Mayor-Romero LC; Department of Medicine, University of Udine and Clinical Neurology, University of Udine, Udine, Italy.
  • Conrad J; Department of Medicine, University of Udine and Clinical Neurology, University of Udine, Udine, Italy.
  • Evers S; Department of Medicine, University of Udine and Clinical Neurology, University of Udine, Udine, Italy.
  • Lochner P; Department of Medicine, University of Udine and Clinical Neurology, University of Udine, Udine, Italy.
  • Roell F; Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogota, Colombia.
  • Brigo F; Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogota, Colombia.
  • Bentes C; Department of Neurology, University of Münster, Munster, Germany.
  • Peralta R; Division for Neurodegenerative Diseases, Department of Neurology, Universitaetsmedizin Mannheim, Heidelberg University, Heidelberg, Germany.
  • Pinho E Melo T; Department of Neurology, University of Münster, Munster, Germany.
  • Keezer MR; Department of Neurology, Krankenhaus Lindenbrunn, Coppenbrugge, Germany.
  • Duncan JS; Department of Neurology, Saarland University Medical Center, Homburg, Germany.
  • Sander JW; Department of Neurology, Saarland University Medical Center, Homburg, Germany.
  • Tettenborn B; Department of Neurology, Hospital Merano (SABES-ASDAA), Merano-Meran, Italy.
  • Koepp M; Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHULN. Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
  • Galovic M; Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHULN. Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Article en En | MEDLINE | ID: mdl-38749674
ABSTRACT

BACKGROUND:

In addition to other stroke-related deficits, the risk of seizures may impact driving ability after stroke.

METHODS:

We analysed data from a multicentre international cohort, including 4452 adults with acute ischaemic stroke and no prior seizures. We calculated the Chance of Occurrence of Seizure in the next Year (COSY) according to the SeLECT2.0 prognostic model. We considered COSY<20% safe for private and <2% for professional driving, aligning with commonly used cut-offs.

RESULTS:

Seizure risks in the next year were mainly influenced by the baseline risk-stratified according to the SeLECT2.0 score and, to a lesser extent, by the poststroke seizure-free interval (SFI). Those without acute symptomatic seizures (SeLECT2.0 0-6 points) had low COSY (0.7%-11%) immediately after stroke, not requiring an SFI. In stroke survivors with acute symptomatic seizures (SeLECT2.0 3-13 points), COSY after a 3-month SFI ranged from 2% to 92%, showing substantial interindividual variability. Stroke survivors with acute symptomatic status epilepticus (SeLECT2.0 7-13 points) had the highest risk (14%-92%).

CONCLUSIONS:

Personalised prognostic models, such as SeLECT2.0, may offer better guidance for poststroke driving decisions than generic SFIs. Our findings provide practical tools, including a smartphone-based or web-based application, to assess seizure risks and determine appropriate SFIs for safe driving.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article